Teladoc Health (NYSE:TDOC – Get Free Report) had its price objective reduced by Bank of America from $16.50 to $13.50 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the health services provider’s stock. Bank of America‘s price objective suggests a potential upside of 5.14% from the company’s current price.
Several other equities analysts have also recently weighed in on TDOC. Citigroup decreased their target price on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, February 21st. Evercore ISI lowered their price objective on shares of Teladoc Health from $15.00 to $14.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. Barclays cut their target price on shares of Teladoc Health from $25.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, April 26th. Cantor Fitzgerald initiated coverage on Teladoc Health in a research report on Thursday, February 29th. They set an “overweight” rating and a $22.00 price target on the stock. Finally, DA Davidson dropped their price objective on Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 21st. Thirteen analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $18.41.
Get Our Latest Report on Teladoc Health
Teladoc Health Stock Up 0.8 %
Shares of TDOC stock opened at $12.84 on Tuesday. The firm’s fifty day moving average price is $14.03 and its two-hundred day moving average price is $17.23. The company has a current ratio of 3.82, a quick ratio of 3.74 and a debt-to-equity ratio of 0.67. Teladoc Health has a 1 year low of $11.88 and a 1 year high of $30.41. The firm has a market capitalization of $2.18 billion, a P/E ratio of -9.11 and a beta of 0.97.
Teladoc Health (NYSE:TDOC – Get Free Report) last released its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.13%. The company had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. During the same period in the prior year, the firm posted ($0.37) EPS. Teladoc Health’s revenue was up 2.7% compared to the same quarter last year. On average, equities analysts predict that Teladoc Health will post -1.04 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, insider Daniel Trencher sold 6,780 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $98,445.60. Following the completion of the sale, the insider now owns 28,192 shares of the company’s stock, valued at $409,347.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Teladoc Health news, CAO Richard J. Napolitano sold 3,765 shares of Teladoc Health stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $54,667.80. Following the completion of the transaction, the chief accounting officer now directly owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel Trencher sold 6,780 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $98,445.60. Following the sale, the insider now owns 28,192 shares of the company’s stock, valued at $409,347.84. The disclosure for this sale can be found here. Insiders have sold 138,368 shares of company stock worth $1,989,227 in the last 90 days. Company insiders own 0.95% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. ICA Group Wealth Management LLC acquired a new stake in Teladoc Health during the fourth quarter worth about $28,000. Hexagon Capital Partners LLC raised its position in shares of Teladoc Health by 204.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after buying an additional 1,065 shares in the last quarter. RIA Advisory Group LLC bought a new stake in shares of Teladoc Health during the 4th quarter worth approximately $36,000. GAMMA Investing LLC acquired a new stake in shares of Teladoc Health during the 4th quarter worth approximately $41,000. Finally, Principal Securities Inc. bought a new position in Teladoc Health in the fourth quarter valued at approximately $45,000. Institutional investors own 76.82% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Read More
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
